{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:01:08Z","timestamp":1770073268629,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This article provides information and a commentary on key trials relevant to the pathophysiology, prevention, and treatment of heart failure (HF) presented at the annual meeting of the European Society of Cardiology held in Stockholm in 2010. Unpublished reports should be considered as preliminary, since analyses may change in the final publication. The SHIFT study supports the use of ivabradine in patients with HF due to left ventricular systolic dysfunction and resting sinus rhythm rate \u226570 b.p.m. despite treatment with beta-blockers or where beta-blockers are contra-indicated. Results from PEARL-HF suggest that the potassium binding polymer RLY5016 may be useful for both prevention and treatment of hyperkalaemia in HF patients with or without concomitant chronic kidney disease. The STAR-heart study provides encouraging observational data about the potential for intracoronary stem cell transplantation in patients with HF. Results from HEBE-III showed no effect of erythropoietin on ejection fraction measured 6 weeks post-MI; although there were fewer cardiovascular events in patients assigned to erythropoietin, the study was too small to provide conclusive evidence of effect.<\/jats:p>","DOI":"10.1093\/eurjhf\/hfq186","type":"journal-article","created":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T13:01:37Z","timestamp":1287666097000},"page":"1261-1264","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Trials Update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL-HF, STAR-heart, and HEBE-III"],"prefix":"10.1093","volume":"12","author":[{"given":"John G.F.","family":"Cleland","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, University of Hull, Daisy Building, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison P.","family":"Coletta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, University of Hull, Daisy Building, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azam","family":"Torabi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, University of Hull, Daisy Building, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniyal","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, University of Hull, Daisy Building, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, University of Hull, Daisy Building, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,1,13]]},"reference":[{"key":"2026020203343535400_ejhfhfq186-bib-0001","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"2026020203343535400_ejhfhfq186-bib-0002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/eurjhf\/hfp154","article-title":"Rationale and design of a randomized double-blind placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic heart failure treatment with the I(f) inhibitor ivabradine trial (SHIFT)","volume":"12","author":"Swedberg","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0003","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0004","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026020203343535400_ejhfhfq186-bib-0005","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/eurjhf\/hfp136","article-title":"Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial","volume":"11","author":"Adamopoulos","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Eng J Med"},{"key":"2026020203343535400_ejhfhfq186-bib-0007","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0008","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/eurjhf\/hfq049","article-title":"Rationale and design of the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF)","volume":"12","author":"Zannad","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0009","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa060186","article-title":"Intracoronary bone marrow derived progenitor cells in acute myocardial infarction","volume":"355","author":"Schachinger","year":"2006","journal-title":"N Eng J Med"},{"key":"2026020203343535400_ejhfhfq186-bib-0010","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa055706","article-title":"Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction","volume":"355","author":"Lunde","year":"2006","journal-title":"N Eng J Med"},{"key":"2026020203343535400_ejhfhfq186-bib-0011","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1161\/CIRCULATIONAHA.105.575118","article-title":"Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months follow-up data from the randomized controlled BOOST trial","volume":"113","author":"Meyer","year":"2006","journal-title":"Circulation"},{"key":"2026020203343535400_ejhfhfq186-bib-0012","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejheart.2007.12.004","article-title":"Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE, and stem cell therapy","volume":"10","author":"Cleland","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0013","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/eurjhf\/hfq095","article-title":"The acute and long term effects of intracoronary stem cell transplantation in 191 patients with chronic heart failure: the STAR-heart study","volume":"12","author":"Strauer","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0014","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/eurjhf\/hfq105","article-title":"Stem cells in heart failure","volume":"12","author":"Domian","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0015","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/eurjhf\/hfp098","article-title":"Design of the reduction in events with darbepoietin alfa in heart failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial","volume":"11","author":"McMurray","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0016","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.jacc.2006.08.031","article-title":"Protective effects of erythropoietin in cardiac ischaemia: from bench to bedside","volume":"48","author":"Lipsic","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026020203343535400_ejhfhfq186-bib-0017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejheart.2007.10.008","article-title":"Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit","volume":"10","author":"Lipsic","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203343535400_ejhfhfq186-bib-0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10557-006-7680-5","article-title":"A single bolus dose of a long acting erythropoietin analogue darbepoietin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study","volume":"20","author":"Lipsic","year":"2006","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026020203343535400_ejhfhfq186-bib-0019","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ahj.2007.12.036","article-title":"Effects of erythropoietin after an acute myocardial infarction: rationale and design of a prospective randomized clinical trial (HEBE-II)","volume":"155","author":"Belonje","year":"2008","journal-title":"Am Heart J"},{"key":"2026020203343535400_ejhfhfq186-bib-0020","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehq304","article-title":"A single dose of erythropoietin in ST-elevation myocardial infarction","author":"Voors","year":"2010","journal-title":"Eur Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfq186","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfq186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hfq186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hfq186","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/11\/1261\/66522515\/eurjhf_12_11_1261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/11\/1261\/66522515\/eurjhf_12_11_1261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:34:47Z","timestamp":1770021287000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/12\/11\/1261\/8435895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,1]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,1,13]]},"published-print":{"date-parts":[[2010,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfq186","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,11]]},"published":{"date-parts":[[2010,11,1]]}}}